Find Clinical Trials

Inclusion Criteria: * Adults aged 18 years and above living in the catchment areas of the 37 health facilities participating in the trial, across the 4 specified municipalities * Individuals who are newly diagnosed with hypertension (defined as systolic blood pressure 140 mmhg or higher and/or diastolic blood pressure 90 mmHg or higher.) and/or diabetes (defined as fasting blood glucose ≥126 mg/dL, random blood glucose ≥200 mg/dL, or Hgb A1c≥6.5). * Individuals with previously known diagnoses of hypertension and/or diabetes with records from health facilities record or patient card of individuals. * Residents of the catchment areas served by the enrolled health facilities in the study sites. Exclusion Criteria: * Individuals with physical or verbal disabilities that would impede their participation in the intervention activities, such as attending and participating in group discussions, counseling sessions, or self-reporting during data collection. * Pregnant women * People who may migrate within a year

Inclusion Criteria: 1. Female patients aged 18 to 75 years. 2. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. 3. Primary breast tumor diameter \> 1 cm. 4. Histologically confirmed invasive ER+/HER2- breast cancer, meeting ER≥50% and Ki67≥10%. HER2 negativity is defined as HER2 immunohistochemistry (IHC) 0-1+, or IHC 2+ with fluorescence in situ hybridization (FISH) confirming no amplification. 5. Clinical tumor stage: cT1c-T4, cN0-cN2, cM0. 6. Willing to undergo breast cancer surgery once surgical criteria are met after neoadjuvant therapy. 7. Adequate organ function, meeting all of the following: * Hemoglobin (Hb)≥90 g/L and patients may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the investigator. Initial treatment must not begin earlier than the day after the erythrocyte transfusion; * Absolute neutrophil count (ANC)≥1.5×10\^9/L; * Platelet count (PLT)≥100×10\^9/L; * Total bilirubin (TBIL)≤1.5×the upper limit of normal (ULN) and patients with Gilbert's syndrome with a total bilirubin ≤2.0 times ULN and direct bilirubin within normal limits are permitted; * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST)≤2.5×ULN; * Alkaline phosphatase (ALP)≤2.5×ULN; * Serum creatinine (Cr)≤1.5×ULN; * Prothrombin time (PT) and activated partial thromboplastin time (APTT)≤1.5×ULN, and international normalized ratio (INR)≤1.5×ULN (in patients not receiving anticoagulation). 8. Left ventricular ejection fraction (LVEF)≥55% at baseline as measured by echocardiography or multi-gated acquisition (MUGA) scan. 9. Women with premenopausal status should receive ovarian suppression with a gonadotropin-releasing hormone agonist such as goserelin or leuprolide before initiation of treatment to become postmenopausal status. Postmenopausal due to surgical/natural menopause requires at least 1 of the following: * prior bilateral oophorectomy; * age≥60 years; * age\<60 years, amenorrheic for at least 12 months (in the absence of chemotherapy, tamoxifen, toremifene, or ovarian suppression), and FSH and estradiol levels in the postmenopausal range. 10. Women of childbearing potential must have a negative serum pregnancy test. Such patients must use a medically acceptable method of contraception during study treatment and for at least 6 months after the last dose of the study drug(s). 11. The subject voluntarily agrees to participate, signs the informed consent form, has good compliance, and is willing to adhere to follow-up. Exclusion Criteria: 1. Stage IV (metastatic) breast cancer or bilateral breast cancer. 2. Prior history of invasive breast cancer. 3. Prior history of ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS). 4. Any prior chemotherapy, endocrine therapy, or anti-HER2 therapy for breast cancer; or prior excisional biopsy of the primary breast tumor and/or axillary lymph nodes, or prior local radiotherapy (excluding diagnostic biopsy for primary breast cancer or surgery for benign breast tumors). 5. Any other malignancy within the past 5 years, except cured cervical carcinoma in situ and non-melanoma skin cancer. 6. Peripheral neuropathy≥Grade 2 per NCI-CTCAE v6.0. 7. Serious cardiovascular or cerebrovascular disease within 6 months prior to randomization, including but not limited to congestive heart failure, unstable angina, severe arrhythmias uncontrolled by medication, severe conduction abnormalities or clinically significant valvular disease, uncontrolled severe hypertension, myocardial infarction, or cerebrovascular accident. 8. Any serious and/or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study (for example, interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, severe renal impairment \[e.g. estimated creatinine clearance \<30ml/min\], history of major surgical resection involving the stomach or small bowel, or preexisting Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea). 9. Major surgery within 4 weeks prior to randomization without full recovery, or an anticipated need for major surgery during study treatment. 10. Known active liver disease, including but not limited to active hepatitis B (defined as HBsAg positive with HBV-DNA≥1000 IU/mL), hepatitis C (defined as HCV-Ab positive with HCV-RNA above the assay's lower limit of quantification), or autoimmune liver disease. 11. Severe and uncontrolled infection or known HIV infection. 12. Active systemic bacterial infection (requiring intravenous antibiotics at time of initiating study treatment) or fungal infection. 13. Pregnant or breastfeeding. 14. Known allergy to the study drug or any of its excipients, or a history of severe hypersensitivity reactions to other monoclonal antibodies. 15. Known abuse of psychotropic substances, alcoholism, or drug abuse. 16. Known, definite neurological or psychiatric disorders associated with poor compliance, including but not limited to epilepsy or dementia. 17. Any other serious physical or mental illness or laboratory abnormality that may increase the risk of study participation or interfere with study treatment and outcomes, or any other condition that, in the investigator's judgment, makes the patient unsuitable for this study. 18. The patient has received an experimental treatment in a clinical trial within the last 30 days or 5 half-lives, whichever is longer, prior to randomization, or is currently enrolled in any other type of medical research (for example: medical device) judged by the sponsor not to be scientifically or medically compatible with this study.

Inclusion Criteria: * Aged 18 years or older * Able to provide informed consent * Evidence of variable airflow limitation within the past 10-years to confirm asthma diagnosis * Meets diagnostic criteria for moderate, or severe asthma * Reports breathlessness impacting daily life physical activities (modified Medical Research Council \[mMRC\] dyspnoea score ≥1) within the past 1-week * Owns a smart device with internet access, which they are willing and able to use for the study duration Exclusion Criteria: * High dependence on medical care * Significant life-limiting comorbidity (\<12 months life expectancy) * Cognitive impairment, poor English language skills or significant untreated hearing impairment that prevents completion of data collection forms or understanding of verbal instructions * Current participation in any other clinical trial, or participation in another clinical trial within the 4-weeks preceding study entry.

Inclusion Criteria: * Provision of signed and dated informed consent form * Male or female, aged 18 years and older * Clinical diagnosis of type 1 or type 2 diabetes and/or prediabetes for any duration * Sufficient venous access for one IV line * Stated willingness to comply with all study procedures and availability for the duration of the study * Willing to wear the required number of CGM systems for the total duration of the study (up to 15 days of total wear), including up to two Argus devices and at least one provided, commercially available, CGM device * Willing and able to use a compatible personal iOS or Android smartphone with - Bluetooth capability to install and use the study application, and to pair and maintain continuous Bluetooth communication between the smartphone and the investigational device for the required wear period * Has reliable access to their personal smartphone for the duration of participation and agrees to keep Bluetooth enabled and the study app running as instructed Exclusion Criteria: * Known or suspected hypersensitivity to any of the components of the investigational device * Known allergy to medical grade adhesives * Presence of any injury, infection, atypical skin condition (such as hyperkeratosis or hyperpigmentation) or tattoo on the wrists * Participation in any clinical trial investigation of a medical device or any medicinal product in clinical development within 30 days * Required or scheduled to have a Magnetic Resonance Imaging (MRI) scan, Computed Tomography (CT) scan, or diathermy during the study wear period * Blood donation or blood loss of more than 500 mL within the last 3 months * Presence of anemia as demonstrated by hematocrit measurements below 36.0% for males or 33.0% for females * Presence of an active implantable medical device such as a pacemaker * Presence or history of a cardiovascular disease including stable and unstable angina pectoris, myocardial infarction, transient ischemic attack, stroke, cardiac decompensation, clinically significant arrhythmias, or clinically significant conduction disorders * Any history or presence of cancer except basal cell skin cancer or squamous cell skin cancer * Presence of signs of acute illness or immunodeficiency Presence of any serious systemic infectious disease during four weeks prior to the intervention * Presence of clinically significant abnormal screening laboratory tests or standard 12 lead electrocardiogram after 5 minutes resting in supine position at screening * History of significant alcohol or drug abuse, or current alcohol consumption exceeding approximately two standard drinks per day for males or one standard drink per day for females * Inability or unwillingness to refrain from smoking for the duration of visits History of diagnosis for hepatitis B, hepatitis C, HIV 1, or HIV 2 * Clinically relevant comorbidity capable of constituting a risk for the participant or interfering with interpretation of data as judged by the investigator, including but not limited to end stage renal disease currently managed by dialysis or anticipating initiating dialysis during the study wear period, current usage of hydroxyurea medications, or significant usage of acetaminophen over 1 g every 6 hours * Mental incapacity, unwillingness, or language barriers precluding adequate understanding or cooperation Pregnancy or current breastfeeding * Current or past affiliation with the investigational site, sponsor, or study personnel, including being an employee, contractor, or immediate family member of any individual directly involved in the trial, or current employment with, contractor relationship with, or significant financial interest in companies involved in glucose monitoring or diabetes related products that could create a conflict of interest or bias study results * Consideration of unsuitability for inclusion by investigator Inability or unwillingness to use a compatible personal smartphone to install and operate the study app and maintain Bluetooth connectivity as required

Inclusion Criteria: * Identify as Latino * Fluent in English or Spanish * 5-15 years old * Referred to individual psychotherapy with a participating clinician for a primary clinical concern involving anxiety, depression, trauma, or disruptive behaviors Exclusion Criteria: \-

Inclusion Criteria: * Individuals with a documented AUD diagnosis * Individuals enrolled in an Intensive Outpatient Program (IOP) (First week enrollment or planned enrollment in Michigan Medicine's Addiction Treatment Services (UMATS) IOP) * Individuals with a Patient Health Questionnaire (PHQ-9) score (≥10, moderate or greater depression symptoms) Exclusion Criteria: * Severe motion sickness or sensitivity to VR-induced nausea or dizziness (anticipated \<10%), medical contraindications to VR use (e.g., seizure disorders, vestibular disorders, agoraphobia, claustrophobia, psychosis). * Significant cognitive impairments that prevent provision of informed consent * Suicidal ideation or plan after consultation with treating clinician * Participants who require vision correction with glasses, unless vision correction is mild (±1), or the participant does not have prescription contact lenses.

Inclusion Criteria: 1. Female, ≥18 years, Egyptian nationality. 2. Breast cancer (any stage) with planned anthracycline containing chemotherapy (intended cumulative DOX ≥240 mg/m² or epirubicin ≥360 mg/m² equivalents). 3. Baseline echo suitable for LVEF ≥53%. 4. Able to consent and comply with follow up. Exclusion Criteria: * • Type 1 and type 2 diabetes; history of diabetic ketoacidosis; pregnancy/lactation. * Symptomatic HF, cardiomyopathy, significant valvular disease, prior anthracycline exposure. * Baseline hypotension (SBP \<95 mmHg), recurrent UTIs/mycotic infections, active foot ulcer/critical limb ischemia. * Inflammatory diseases, liver and kidney diseases. * Autoimmune diseases. * Other type of malignancies or metastatic diseases. * Patients who exposed to surgery less than one month. * Concomitant dexrazoxane planned upfront (allowed only for rescue; documented). * Known hypersensitivity to study drugs.

Inclusion Criteria: * Participants enrolled in Detroit Research on Cancer Survivors (Detroit ROCS) * Diagnosis of Primary Breast, prostate, or colorectal cancer on or after 1/1/2013 * have received or currently receiving care at Karmanos Cancer Institute * meet one or more of the National Comprehensive Cancer Network (NCCN) guidelines for cancer genetic testing as described below Female breast 1. personal diagnosis at age ≤50 2. personal history of the triple-negative subtype 3. at least 1 close (first- or second-degree) relative diagnosed with breast cancer at age \<50 4. at least 1 close relative diagnosed with ovarian cancer 5. 2+ close relatives diagnosed with breast or prostate cancer 6. age \<50 AND another primary breast cancer at any age 7. 2+ primary breast cancers at any age OR Prostate 1. personal history of high-risk or very high-risk prostate cancer 2. personal history of regional or metastatic prostate cancer 3. personal history of less than high-risk prostate cancer with a suggestive family history (i.e., father or brother or multiple relatives with prostate cancer diagnosed at age \<60; at least 1 relative with breast, ovarian, or pancreatic cancer; or at least 1 relative with colorectal, ovarian, pancreatic, or kidney cancer) OR Colorectal 1. personal diagnosis at age ≤50 2. at least 1 close relative diagnosed with HNPCC at age \<50 3. at least 2 close relatives diagnosed with an HNPCC cancer at any age 4. colorectal and \>=1 primary endometrial, ovarian, gastric, pancreatic, or prostate Exclusion Criteria: * Previous genetic counseling and/or testing

Inclusion Criteria: * Age ≥ 18 years * Scheduled for elective coronary artery bypass graft (CABG) surgery * American Society of Anesthesiologists (ASA) physical status II-III * Planned use of extracorporeal circulation during surgery * Ability to provide written informed consent Exclusion Criteria: * Age \< 18 years * ASA physical status other than II-III * Emergency surgery * Pregnancy * History of neurological disease affecting consciousness or decision-making capacity * History of psychiatric disease affecting decision-making capacity * History of head trauma within the previous 24 hours * Presence of carotid artery stenosis or significant carotid artery disease * Coagulation disorders (INR \> 1.25, aPTT \> 35 s, or platelet count \< 100,000/μL) * Reoperation (redo cardiac surgery) * Congestive heart failure * Chronic kidney failure * Sepsis * Hypoxia * Ocular trauma * Optic nerve pathology

Inclusion Criteria: * Diagnosis of first ischemic or hemorrhagic stroke verified by Computerized Axial Tomography or Magnetic Resonance * Age above 18 years * Mini Mental State Examination ≥ 24 * Latency from the event \< 3 months * Presence of clinically significant anxiety and/or depression (Generalized Anxiety Disorder and/or Patient Health Questionnaire ≥10) * Onset of acute event not more than 90 days prior to enrollment in the study Exclusion Criteria: * Clinical instability * Lesions dated over 3 months from onset * Multiple or bilateral lesions * Mini Mental State Examination \< 24 * Previous or concomitant neurological, psychiatric, or internal pathologies found in the year preceding the study that, in the judgment of the clinical investigator, may affect the psychological condition and/or interfere with study procedures * Behavioral/cognitive disorders that prevent adequate patient compliance with treatment * Therapeutic-rehabilitative treatments with music in the year preceding the study * Previous musical skills (training or musical practice lasting more than 3 years) * Refusal or impossibility to sign informed consent For the subgroup of patients subjected to functional Magnetic Resonance, the following exclusion criteria will also be taken into account: * Incompatibility with the execution of the MRI investigation (e.g., ascertained or possible presence of metal in the body; claustrophobia; sickle cell anemia) * Inability to understand or provide informed consent for the execution of the MRI investigation

Inclusion Criteria: * Adults aged 18 years or older * Diagnosed with at least one chronic disease (e.g., diabetes mellitus, hypertension, cardiovascular disease, chronic respiratory disease, chronic kidney disease) for a minimum duration of six months * Prescribed long-term medication therapy * Able to understand and respond to the study questionnaire * Willing to provide written informed consent Exclusion Criteria: * Patients with acute medical conditions requiring immediate care * Individuals with severe cognitive impairment or psychiatric illness that would preclude reliable participation * Patients who are terminally ill * Patients unwilling to participate or provide consent

Inclusion Criteria: T2D Cohort: * A clinical diagnosis of T2D ≥ 1 year * HbA1c ≥ 6.5% (pre-index date) * Initiated semaglutide or other AHA(s) before January 1st, 2023\* * Seen by an LMC endocrinologist in the last 18 months as of the query date * ≥ one HbA1c value up to 6 months (+ 90 days) prior to index date * Informed data consent for their medical record data to be used for research purposes Obesity Cohort: * 18 years or older * BMI ≥ 27 kg/m2 * HbA1c \< 6.5% (pre-index date) * Initiated semaglutide before January 1st, 2023\* * Seen by an LMC endocrinologist in the last 18 months as of the query date * ≥ one HbA1c value up to 6 months (± 90 days) prior to index date * Informed data consent for their medical record data to be used for research purposes Exclusion Criteria: * Clinical diagnosis of type 1 diabetes/latent autoimmune diabetes in adults (LADA) * Clinical diagnosis of T2D (obesity cohort only) * Are pregnant at the time of semaglutide or other AHA initiation or became pregnant during follow-up period * Documented history or family history of medullary thyroid carcinoma * Participation in a research study with an Investigational Product * eGFR \< 15 mL/min/1.73m2 at index date * Use of non-semaglutide GLP-1-based medication for more than 6 months after the index date (T2D sema cohort and obesity sema cohort) * Use of other AHA for more than 6 months after the index date within the first year of semaglutide use (T2D sema cohort and obesity sema cohort)

Inclusion Criteria: * from 18 to 25 yrs medical student Exclusion Criteria: * less than 18 yrs

Inclusion Criteria: * Adults aged between 18 and 65 years. * Clinically diagnosed asthma confirmed by a physician. * Stable asthma condition (no acute exacerbation in the last 4 weeks). * Receiving regular medical treatment for asthma. * Able to understand and follow instructions for the intervention. * Willing to participate and provide written informed consent. Exclusion Criteria: * Diagnosis of chronic respiratory diseases other than asthma (e.g., COPD, bronchiectasis). * Acute asthma exacerbation within the last 4 weeks. * Severe cardiovascular, neurological, or musculoskeletal conditions that may limit participation in physical activity. * Current participation in another structured exercise or rehabilitation program. * History of major psychiatric disorders that may interfere with participation (e.g., psychotic disorders). * Pregnancy. * Cognitive impairment affecting the ability to follow instructions.

Main Inclusion Criteria: * Participants with advanced adenocarcinoma of the breast and must have received prior adequate therapy in accordance with local practice for their tumor type and stage of disease. * Metastatic or locoregionally recurrent disease and radiological or objective evidence of progression on or after the last systemic therapy prior to starting investigational medicinal products. * Eastern cooperative oncology group (ECOG)/World Health Organization (WHO) performance status 0 to 1, and a minimum life expectancy of 12 weeks. * At least one lesion that is measurable and/or non-measurable, as per RECIST 1.1 and that can be accurately assessed at baseline and is suitable for repeated assessment by computed tomography (CT), magnetic resonance imaging (MRI), or plain X-ray, or clinical examination. * Menopausal status * Pre-menopausal women must start GnRH agonist therapy at least 4 weeks before study treatment and continue throughout the study. * Post-menopausal women must meet one of these criteria: bilateral oophorectomy, age ≥60 years, age ≥50 years with ≥12 months amenorrhea and intact uterus without hormonal therapy, or age \<60 years with ≥12 months amenorrhea and post-menopausal hormone levels. * Histological or cytological confirmation of adenocarcinoma of the breast. * Participants of childbearing potential must agree to use one highly effective contraceptive measure. * Documentation of ER-positive tumor irrespective of progesterone receptor status. Main Exclusion Criteria: * A participant who has received 2 or more lines of CDK4/6 inhibitors in the advanced disease setting. * A participant who has received prior camizestrant or atirmociclib treatment in the advanced disease setting. * Patients previously treated with other next generation selective estrogen receptor degrader (SERDs) or other experimental ETs in the advanced disease setting. * Patients previously treated with other experimental cyclin-dependent kinase (CDK) inhibitors are not eligible. * Inability to swallow oral medications. * Any unresolved toxicities of Grade ≥ 2 from prior anti-cancer therapy (with the exception of alopecia). * Presence of life-threatening metastatic visceral disease. * Any evidence of severe or uncontrolled systemic diseases. * Contraindication to or known intolerance/hypersensitivity of/to camizestrant or atirmociclib.

Inclusion Criteria: * Volunteering to participate in the study * Being in the early postmenopausal period (no more than 8 years have passed since menopause) * Having experienced natural menopause * Having had at least one pregnancy * Residing in Istanbul or Izmir provinces Exclusion Criteria: * History of trauma or illness that would prevent exercise * Having received hormone replacement therapy * Being involved in a different exercise program * Presence of a severe cardiopulmonary, orthopedic, or neurological disease * Presence of a psychological or psychiatric diagnosis * Presence of physical discomforts such as severe dizziness * Cooperation problems and incompatibility

Inclusion Criteria: 1. Age 18 to 80 years (inclusive). 2. Confirmed diagnosis of type 2 diabetes mellitus (T2DM). 3. HbA1c between 8.0% and 13.0% (inclusive) within the last 1 month prior to screening/enrollment. 4. Planned to receive insulin therapy for at least 6 months after hospital discharge, as assessed/confirmed by the treating physician (principal physician). Exclusion Criteria: 1. Current use of a real-time continuous glucose monitoring (RT-CGM) device, or use within the 3 months prior to enrollment. 2. Severe skin disease at the sensor insertion site, or allergy to adhesive tape/adhesives. 3. Pregnant women; positive pregnancy test at screening; or planning pregnancy during the study period. 4. Currently participating in, or planning to participate in, another clinical trial. 5. Current use of oral corticosteroid therapy, or anticipated use during the trial period. 6. Severe liver disease, defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>3 times the upper limit of normal (ULN). 7. Severe renal impairment or end-stage renal disease, defined as estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73 m². 8. Any condition that, in the investigator's opinion, makes the participant unsuitable for the trial, for example: history of ocular trauma or other diagnosed eye diseases causing visual impairment; unwillingness to participate or inability to adequately understand/comply due to speech/language impairment; or presence of psychiatric disorders.

Inclusion Criteria: 1. Participants provide informed consent and confirm that they are able and willing to comply with all protocol requirements. 2. Participants must be ≥ 18 years and \< 80 years of age and competent to give informed consent. 3. Eastern Cooperative Oncology Group performance status ≤ 2. 4. Diagnosis of either CRC (confirmed by histopathology), GC (confirmed by histopathology), PDAC (confirmed by cytology or histopathology), ILC (confirmed by histopathology), or EOC (suspected or confirmed by cytology or histopathology). 5. Women of childbearing potential (WOCBP) should have a negative serum test at screening (Visit 1) and a negative urine pregnancy test at the PET/CT imaging visit (Visit 2) prior to \[18F\]FPyQCP administration. 6. WOCBP, and men who are sexually active with WOCBP, must agree to use a highly effective method(s) of contraception for the duration of the study 7. Cohort A specific: Participants with stage I-III (see Appendix 3) CRC, GC, PDAC, ILC, or EOC (stage IV disease is allowed in the setting of oligometastatic disease \[5 or fewer known metastases) as assessed by conventional imaging within 8 weeks of \[18F\]FPyQCP administration. 8. Cohort B specific: Conventional imaging performed within 8 weeks of screening and no later than 24 hours before \[18F\]FPyQCP administration and available for upload to the central imaging vendor, including, at a minimum, a contrast-enhanced CT that includes the abdomen and pelvis. 9. Either: 1. Treatment-naïve with at least stage IIB disease. Available biopsy sample or scheduled biopsy or surgical resection no later than Day 42. 2. Following neoadjuvant therapy (with at least stage IIB disease at initial presentation) with scheduled biopsy or surgical resection no later than Day 42. \[18F\]FPyQCP PET/CT imaging should be performed as close to scheduled procedure as clinically feasible. 3. Suspected recurrence after definitive therapy Exclusion Criteria: 1. Participants administered any radioisotope within 5 physical half-lives prior to \[18F\]FPyQCP administration. 2. Participants administered any other IMP within 2 weeks or 5 half-lives, whichever is longest, prior to \[18F\]FPyQCP administration. 3. Participants who have recently received any other contrast agent (\< 24 hours for intravenous agents and \< 5 days for oral agents) before the day of \[18F\]FPyQCP administration. 4. Participants with a history of severe claustrophobia or panic attacks when in confined spaces. 5. Known hypersensitivity to \[18F\]FPyQCP or any of its constituents. 6. Participants with any medical condition or other circumstances at screening or in their past medical history that, in the opinion of the investigator, compromise obtaining reliable data, achieving study objectives, or study completion. 7. Known diagnosis of an autoimmune or inflammatory disorder that is expected to confound image interpretation per investigator judgment, excluding disorders directly related to the index cancer (e.g. tumor-associated pancreatitis or biliary stasis for PDAC). 8. Medical history of abdomino-pelvic or breast irradiation in the last 3 months. 9. Presence of any current implanted foreign material (e.g. stents, surgical clips) that may confound image interpretation per investigator judgment. 10. Significant renal or hepatic impairment. 11. Female participants who are breastfeeding, unless the participant commits to pumping breast milk and discarding it from injection to ≥ 24 hours from the time of the \[18F\]FPyQCP administration. 12. Cohort A Specific Exclusion Criteria: 12. No prior history of any other cancer, unless treated with curative-intent and disease-free for at least 5 years before Visit 1 (at least 1 year before Visit 1 for basal cell carcinoma, localized squamous cell carcinoma of the skin and in situ carcinoma of cervix).

Inclusion Criteria: * Age ≥ 18 years * Female sex * Patient with scheduled surgical procedure for removal of a breast lesion * Patient who was informed by the surgeon at the preoperative consultation and having signed the consent form * Free subject, without guardianship, curatorship or subordination * Patients benefiting from a social security scheme or benefiting from such a scheme through a third party Exclusion Criteria: * Persons benefiting from enhanced protection, i.e. minors, persons deprived of their liberty by judicial or administrative decision, people staying in a health or social establishment, adults under legal protection and patients in emergency situations * Pregnant or breast-feeding women.

Inclusion Criteria: * Delivery of a healthy, singleton infant 2-60 months before enrollment in the study * Current involvement in caregiving or regular contact with the child in question * Patient Health Questionnaire-9 (PHQ-9) pre-treatment score of ≥ 5 * Age ≥ 22, but ≤ 60 years * Ability to determine the motor threshold of the participant. The participant's motor threshold could be established as the minimum stimulus required to induce contraction of the finger * Subjects willing and able to abstain from partaking in any treatments other than the pre-procedure therapy regime for the treatment of depressive symptoms and/or urinary incontinence, including non-invasive brain stimulation treatments other than the study procedure during study participation * Willingness to comply with study instructions and to return to the clinic for the required visits * Subjects are required to use birth control measures throughout the study if there is a reasonable possibility they could become pregnant during the study * If applicable, subjects will be maintained on a pre-study psychotherapeutic regimen and/or prescribed neuropsychiatric medications at a stable therapeutic dosage for at least 1 month prior to study entry Exclusion Criteria: * Metallic objects in or near the head * rTMS devices are contraindicated for use in patients who have conductive, ferromagnetic or other magnetic-sensitive metals implanted in their head or within 12 in (30 cm) of the treatment coil\* * Implanted stimulator devices, implanted defibrillators, implanted neurostimulators * Cardiac pacemakers * Electronic implants * Metal implants * rTMS devices are contraindicated for use in patients who have active or inactive implants (including device leads), including deep brain stimulators, cochlear implants, ocular implants and vagus nerve stimulators. Contraindicated use could result in serious injury or death. * Drug pumps * Application in the heart area * Application of HPM-6000UF in the head area * Persons with a tendency to seizure (e.g., persons suffering from hypotonia and epilepsy) * Anticoagulation therapy * Severe or life-threatening condition * Pulmonary insufficiency * Heart disorders * Renal insufficiency * Decompensated\*\* hemorrhagic conditions * Decompensated\*\* blood coagulation disorders * Decompensated\*\* cardiovascular diseases * Malignant tumor or benign tumor * Fever * Pregnancy Study specific: * Active suicidal intent * History of suicide attempts in the last 3 years before enrollment in the study * Substance-induced depression or depression secondary to a general medical condition * Diagnosis of seasonal affective disorder, psychotic disorder including schizoaffective disorder or current psychotic symptoms, major depression with psychotic features, bipolar disorder, borderline personality disorder * Current episodes of substance abuse * Substance dependence 3 months before enrollment in the study * History or concurrent use of electroconvulsive therapy or vagus nerve stimulation * Neurological disorders, including a history of seizures, cerebrovascular disease, primary or secondary tumors in CNS, cerebral aneurysm, dementia, or movement disorders * History of increased intracranial pressure or head trauma * Any other disease or condition at the investigator's discretion that may pose risk to the patient or compromise the study * Examples include cochlear implants, implanted electrodes/stimulators, aneurysm clips or coils, stents, bullet fragments, jewelry and hair barrettes. Failure to follow this restriction could result in serious injury or death. Certain exceptions apply to mouth implants such as standard amalgam dental fillings, single post dental implants, dental bridge work, and braces. If these items are present, the therapy can still be administered. \*\*By means of decompensation, it means a patient with a proven medical history of the decompensated health condition and long-term medication. Patients who use certain medications only for preventive purposes, without any proven previous health condition failure are not considered contraindicated.